3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Hepatocellular
52
Carcinoma, Renal Cell
25
Liver Neoplasms
23
Neoplasms
19
Carcinoma, Non-Small-Cell Lung
16
Breast Neoplasms
16
Kidney Neoplasms
11
Leukemia, Myeloid, Acute
9
Melanoma
8
Glioblastoma
8
Sarcoma
7
Prostatic Neoplasms
7
Neoplasm Metastasis
7
Brain Neoplasms
7
Thyroid Neoplasms
6
Ovarian Neoplasms
6
Lung Neoplasms
6
Pancreatic Neoplasms
5
Gliosarcoma
5
Urinary Bladder Neoplasms
4
Recurrence
4
Leukemia, Myelomonocytic, Chronic
4
Leukemia
4
Carcinoma
4
Rectal Neoplasms
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Myelodysplastic Syndromes
3
Multiple Myeloma
3
Leukemia, Lymphocytic, Chronic, B-Cell
3
Leiomyosarcoma
3
Interventions
Sorafenib
1
Irinotecan
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Vaccinia
×
Sorafenib
×
Clear all
NCT02562755
2020-12-16
PHOCUS
SillaJen, Inc.
Phase 3
Completed
459 enrolled
12 charts